Opportunity Pharma and OpenEye, Cadence Molecular Sciences join forces to power decision-making for drug discovery investors <26 SEPTEMBER 2023> <ALDERLEY PARK, UK> Opportunity Pharma and OpenEye, Cadence Molecular Sciences, have signed an agreement whereby Opportunity Pharma will utilise OpenEye&rs.
Drug discovery will benefit from a virtual artificial intelligence (AI) expert thanks to Opportunity Pharma and OpenEye, Cadence Molecular Sciences joining forces.